These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27500678)

  • 1. [The prospects for the application of the natural and preformed therapeutic factors in the treatment of non-alcoholic fatty liver disease].
    Zabolotnaya IB
    Vopr Kurortol Fizioter Lech Fiz Kult; 2016; 93(4):42-48. PubMed ID: 27500678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effectiveness of the spa and health resort-based treatment with the application of Essentuki-type drinking mineral waters for the management of non-alcoholic fatty liver disease in the patients presenting with type 2 diabetes mellitus].
    Efimenko NV; Kaĭsinova AS; Fedorova TE; Botvineva LA
    Vopr Kurortol Fizioter Lech Fiz Kult; 2015; 92(3):14-17. PubMed ID: 26285328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subclinical hypothyroidism in patients with non-alcoholic fatty liver disease at the background of carbohydrate metabolism disorders.
    Feisa SV; Chopei IV
    Wiad Lek; 2018; 71(2 pt 1):261-264. PubMed ID: 29729151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
    Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
    World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Possibilities for the use of ursodeoxycholic acid in the treatment of patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease].
    Rasskazova MA; Vorobyev SV; Butova HN
    Ter Arkh; 2023 May; 95(4):316-321. PubMed ID: 38158979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The diagnostics and clinical pattern of nonalcoholic fatty liver disease in patients with pre-diabetes and type 2 diabetes and obesity].
    Чубірко КІ
    Wiad Lek; 2017; 70(2):208-212. PubMed ID: 28511161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
    Guo M; Xi G; Yang N; Yao H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
    Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
    J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes].
    Чопей ІВ; Івачевська ВВ; Чубірко КІ; Гряділь ТІ; Гечко ММ
    Wiad Lek; 2017; 70(2):169-173. PubMed ID: 28511152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
    Cernea S; Cahn A; Raz I
    Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
    Cariou B; Staels B
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1441-8. PubMed ID: 25164277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comorbidity severity index as a new tool for assessment of co-existing diseases in patients with non-alcoholic fatty liver disease at the carbohydrate metabolism disorder background and concomitant subclinical hypothyroidism.
    Feysa SV; Chopei IV
    Wiad Lek; 2019; 72(4):650-653. PubMed ID: 31055550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The advantages of drinking mineral water in the rehabilitation of patients with viral hepatitis C with accompanying non-alcoholic fatty liver disease after suffering from COVID-19.
    Dragomiretska N; Zabolotna I; Gushcha S; Sierpińska L; Izha G; Plakida A; Bezverhnyuk T
    Ann Agric Environ Med; 2023 Jun; 30(2):266-272. PubMed ID: 37387376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
    Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
    Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Balneotherapeutics of non-alcoholic fatty liver disease with the use of the Essentuki-type drinking mineral waters].
    Fedorova TE; Efimenko NV; Kaĭsinova AS
    Vopr Kurortol Fizioter Lech Fiz Kult; 2012; (6):21-3. PubMed ID: 23373292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [State of intestinal microbiota in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease].
    Lytvynenko KO; Bodnar PM; Lysiana TO; Ponomar'ova IH; Koval'chuk OA
    Lik Sprava; 2014; (5-6):82-7. PubMed ID: 25906652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease.
    Byrne CD
    Proc Nutr Soc; 2013 Nov; 72(4):412-9. PubMed ID: 23668723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Features of clinical, biochemical, and sonographic parameters in patients with chronic viral hepatitis C with concomitant non-alcoholic fatty liver disease.
    Izha G; Dragomiretska N; Gushcha S; Sierpińska LE; Plakida A
    Ann Agric Environ Med; 2023 Mar; 30(1):49-54. PubMed ID: 36999855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
    Chen S; Zhao X; Ran L; Wan J; Wang X; Qin Y; Shu F; Gao Y; Yuan L; Zhang Q; Mi M
    Dig Liver Dis; 2015 Mar; 47(3):226-32. PubMed ID: 25577300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.